Shien Guo

1.1k total citations
61 papers, 571 citations indexed

About

Shien Guo is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Shien Guo has authored 61 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Oncology and 16 papers in Genetics. Recurrent topics in Shien Guo's work include Multiple Myeloma Research and Treatments (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Hemoglobinopathies and Related Disorders (9 papers). Shien Guo is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Hemoglobinopathies and Related Disorders (9 papers). Shien Guo collaborates with scholars based in United States, France and Italy. Shien Guo's co-authors include Michael A. Counte, Arman Altincatal, Glenn Phillips, Ling Shi, Kathleen N. Gillespie, Kathleen W. Wyrwich, Rossella Medori, Julia Braverman, Jacob Elkins and Elizabeth Kinter and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shien Guo

56 papers receiving 559 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shien Guo United States	16	215	170	158	114	100	61	571
Sytske Anne Bergstra Netherlands	15	157 0.7×	56 0.3×	82 0.5×	48 0.4×	82 0.8×	59	759
Miguel Bernardes Portugal	18	204 0.9×	65 0.4×	156 1.0×	84 0.7×	168 1.7×	99	948
Sheila R. Reddy United States	12	60 0.3×	75 0.4×	41 0.3×	49 0.4×	30 0.3×	32	381
Michael W. Pill United States	9	55 0.3×	88 0.5×	285 1.8×	24 0.2×	15 0.1×	10	531
Serena Brancati Italy	10	70 0.3×	73 0.4×	47 0.3×	43 0.4×	44 0.4×	20	370
L. Chen United States	13	112 0.5×	77 0.5×	87 0.6×	165 1.4×	69 0.7×	21	744
Claudio Romani Italy	17	304 1.4×	234 1.4×	98 0.6×	62 0.5×	97 1.0×	33	748
Jesús Tornero Spain	14	111 0.5×	70 0.4×	64 0.4×	103 0.9×	66 0.7×	35	738
Farrah Pompilus United States	9	45 0.2×	65 0.4×	39 0.2×	94 0.8×	19 0.2×	23	357
Krista Schroeder United States	9	81 0.4×	32 0.2×	71 0.4×	51 0.4×	34 0.3×	16	587

Countries citing papers authored by Shien Guo

Since Specialization

Citations

This map shows the geographic impact of Shien Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shien Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shien Guo more than expected).

Fields of papers citing papers by Shien Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shien Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shien Guo. The network helps show where Shien Guo may publish in the future.

Co-authorship network of co-authors of Shien Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Shien Guo. A scholar is included among the top collaborators of Shien Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shien Guo. Shien Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guo, Shien, et al.. (2026). Experimental investigation of downstream temperature and radiative heat flux in turbulent combustion of sloped solar photovoltaic (PV) panel fires under varying geometries. Applied Thermal Engineering. 289. 129755–129755.

Musallam, Khaled M., et al.. (2024). Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia. Blood. 144(Supplement 1). 3857–3857. 1 indexed citations

Olíva, Esther Natalie, Uwe Platzbecker, Matteo Giovanni Della Porta, et al.. (2024). Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study. Blood. 144(Supplement 1). 3216–3216. 2 indexed citations

Cella, David, Christine de la Loge, Shien Guo, et al.. (2024). The Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation. Journal of Patient-Reported Outcomes. 8(1). 92–92. 4 indexed citations

Taher, Alì, Khaled M. Musallam, Vip Viprakasit, et al.. (2023). Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia. BMJ Open. 13(3). e066683–e066683. 4 indexed citations

Schadendorf, Dirk, Hussein A. Tawbi, Evan J. Lipson, et al.. (2023). Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. European Journal of Cancer. 187. 164–173. 9 indexed citations

Fu, Dong‐Jing, et al.. (2023). Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry. 23(1). 587–587. 10 indexed citations

Gordon, Leo I., Fei‐Fei Liu, Julia Braverman, et al.. (2023). Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica. 109(3). 857–866. 6 indexed citations

Delforge, Michel, Krina K. Patel, Devender Dhanda, et al.. (2023). Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial. Blood. 142(Supplement 1). 96–96. 2 indexed citations

10.

Hengstenberg, Christian, Nicolas M. Van Mieghem, Xiaomei Ye, et al.. (2023). Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial. The American Journal of Cardiology. 209. 212–219. 1 indexed citations

11.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.

12.

Santini, Valeria, António Almeida, Aristoteles Giagounidis, et al.. (2017). The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma Myeloma & Leukemia. 18(2). 136–144.e7. 15 indexed citations

13.

Phillips, Glenn, Shien Guo, Randall H. Bender, et al.. (2016). Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Multiple Sclerosis and Related Disorders. 6. 66–72. 17 indexed citations

14.

Guo, Shien, et al.. (2014). Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease. PharmacoEconomics. 32(11). 1129–1139. 19 indexed citations

15.

Guo, Shien, et al.. (2014). Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches. PharmacoEconomics. 32(6). 559–572. 23 indexed citations

16.

Vollmer, Timothy, Eva Havrdová, Krzysztof Selmaj, et al.. (2013). Daclizumab High-Yield Process Treatment Reduced the Impact of Multiple Sclerosis Relapse on Health-Related Quality of Life (Results of the SELECT Trial) (P03.212). Neurology. 80(7_supplement). 1 indexed citations

17.

Guo, Shien, Alexandra Ward, Judith A. O’Brien, et al.. (2009). Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a. PharmacoEconomics. 27(1). 39–53. 22 indexed citations

18.

Guo, Shien, et al.. (2005). Physician adoption of hyperbaric oxygen therapy in the treatment of chronic wounds.. PubMed. 51(10). 46–58. 1 indexed citations

19.

Guo, Shien, et al.. (2003). COST-EFFECTIVENESS OF ADJUNCTIVE HYPERBARIC OXYGEN IN THE TREATMENT OF DIABETIC ULCERS. International Journal of Technology Assessment in Health Care. 19(4). 731–737. 31 indexed citations

20.

Guo, Shien, Michael A. Counte, & James C. Romeis. (2003). HYPERBARIC OXYGEN TECHNOLOGY: AN OVERVIEW OF ITS APPLICATIONS, EFFICACY, AND COST-EFFECTIVENESS. International Journal of Technology Assessment in Health Care. 19(2). 339–346. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact